At the Heart of Innovation: PARCC Welcomes Inserm and AXA Delegations
The PARCC – Paris Cardiovascular Research Center was honored to host a high-level delegation from Inserm, the Inserm Foundation, and AXA for a strategic site visit and immersion into the future of cardiovascular medicine.
This meeting highlighted the scientific excellence of our research teams and underscored the crucial role of corporate philanthropy in accelerating breakthroughs for patient benefit.
✨ Three PARCC Teams, Three Medical Frontiers
Led by our Director, Dr. Jean-Sébastien Silvestre, the visit offered our guests an inside look at disruptive projects redefining cardiovascular and renal health:
- Treatment 2.0: Professor Hafid Ait-Oufella presented his work on immuno-metabolism, exploring how to harness the immune system to “heal the heart.”
- Women’s Arterial Health: Dr. Nabila Bouatia-Naji addressed the urgent need for personalized medicine, a major global public health priority for women.
- Xenotransplantation: Professor Alexandre Loupy shared his revolutionary vision of “on-demand” organs to solve the critical shortage of donor grafts.
A Dialogue Between Science and Commitment
The visit fostered a constructive dialogue on how strategic partnerships bridge the gap between fundamental research and clinical solutions. We would like to warmly thank all participants for these insightful exchanges:
- From Inserm: Professor Didier Samuel (Chairman and CEO of Inserm & President of the Inserm Foundation) and Damien Rousset (Deputy Director General).
- From AXA: Mathieu Godart (CEO, AXA France), Diane Milleron-Deperrois (CEO, AXA Santé), Clément Rouxel (General Delegate, AXA Fund for Human Progress), and Julia d’Astorg (Director, AXA Research Fund).
We extend our deepest gratitude to the leadership of the Inserm Foundation, specifically Pierre-Louis Autin (Executive Director) and Frédérique Chegaray (Director of Philanthropy), for their instrumental role in developing these strategic partnerships and their unwavering support for our center’s global influence.
Together, we are transforming cutting-edge science into concrete hope for patients.
